Comparable stake leader
Quanterix Corp
SEC ownership of Akoya Biosciences, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001711933.
Disclosed value leader
Quanterix Corp
Comparable rows
1/6
Latest evidence
28 Apr 2025
- Parsed ownership sources
-
13D/G and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Quanterix Corp
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
1 of 6
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Quanterix Corp
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
28 Apr 2025
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001711933
- Issuer location
- Marlborough, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Akoya Biosciences, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Quanterix Corp
Disclosed value leader
Quanterix Corp
Comparable rows
1/6
Latest evidence
28 Apr 2025
13D/G
3/4/5
Lead comparable stake: 56%
5 rows are not safely comparable across share classes.
13D/G row: Quanterix Corp
Quick read
Quanterix Corp leads the comparable SEC ownership view at 56%.
1 of 6 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Quanterix Corp's linked filing trail.
Comparable ownership
Top 1
Quanterix Corp
56%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 6 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Quanterix Corp |
13D/G
Quanterix Corporation
|
56%
|
$38,811,973
30,560,609 shares
|
+$3,615,179 | 28 Apr 2025 |
| Joseph Driscoll |
3/4/5
Chief Financial Officer
|
—
mixed-class rows
|
$1,174,793
373,458 shares
mixed-class rows
|
— | 22 Dec 2022 |
| Frederic Pla |
3/4/5
Chief Operating Officer
|
—
mixed-class rows
|
$581,985
191,500 shares
mixed-class rows
|
— | 23 Mar 2024 |
| Marilee Moy |
3/4/5
CHIEF PEOPLE OFFICER
|
—
mixed-class rows
|
$89,508
60,000 shares
mixed-class rows
|
— | 23 Feb 2023 |
| Ehab El-Gabry |
3/4/5
Chief Medical Officer
|
—
mixed-class rows
|
$72,725
48,750 shares
mixed-class rows
|
— | 23 Feb 2023 |
| Garry Ph.D. Nolan |
3/4/5
Director
|
—
class O/S missing
|
—
56,322 shares
|
— | 01 Jun 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 06 Oct 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-16 of 16 reporting-owner rows connected to Akoya Biosciences, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
16
Largest Forms 3/4/5 holder
Joseph Driscoll
Net 12M change
$0
Latest report
08 Jul 2025
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Joseph Driscoll | Chief Financial Officer | $1,174,793 | Mixed | 22 Dec 2022 | ||
| Frederic Pla | Chief Operating Officer | $581,985 | Mixed | 23 Mar 2024 | ||
| Marilee Moy | Chief People Officer | $89,508 | Mixed | 23 Feb 2023 | ||
| Ehab El-Gabry | Chief Medical Officer | $72,725 | Mixed | 23 Feb 2023 | ||
| Jennifer Kamocsay | Chief Legal Officer | $0 | Mixed | 08 Jul 2025 | ||
| Goldman Myla Lai | Director | $0 | Mixed | 08 Jul 2025 | ||
| Pascal Bamford | Chief Clinical Officer | $0 | Mixed | 08 Jul 2025 | ||
| Scott Mendel | Director | $0 | Mixed | 08 Jul 2025 | ||
| Brian McKelligon | President and CEO, Director | $0 | Mixed | 08 Jul 2025 | ||
| Thomas A. Raffin | Director | $0 | Mixed | 08 Jul 2025 | ||
| Ph.D. Niro Ramachandran | Chief Business Officer | $0 | Mixed | 08 Jul 2025 | ||
| John Frederick Ek | Cfo | $0 | Mixed | 08 Jul 2025 | ||
| Matthew Winkler | Director | $0 | Mixed | 08 Jul 2025 | ||
| Robert G. Shepler | Director | Mixed | 08 Jul 2025 | |||
| Thomas P. Schnettler | Director | Mixed | 08 Jul 2025 | |||
| Garry Ph.D. Nolan | Director | Mixed | 01 Jun 2023 |
Recent insider transactions for Akoya Biosciences, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.